



(86) Date de dépôt PCT/PCT Filing Date: 2003/04/17
(87) Date publication PCT/PCT Publication Date: 2003/10/30
(85) Entrée phase nationale/National Entry: 2004/10/06
(86) N° demande PCT/PCT Application No.: US 2003/012013
(87) N° publication PCT/PCT Publication No.: 2003/088976
(30) Priorité/Priority: 2002/04/19 (10/127,005) US

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/59, C07C 401/00

(71) Demandeur/Applicant:
BONE CARE INTERNATIONAL, INC., US

(72) Inventeurs/Inventors:
MAZESS, RICHARD B., US;
STRUGNELL, STEPHEN A., US;
KNUTSON, JOYCE C., US

(74) Agent: TORYS LLP

(54) Titre : PROCEDE DESTINE AU TRAITEMENT ET A LA PREVENTION DE L'HYPERPARATHYROIDISME
(54) Title: METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM

(57) **Abrégé/Abstract:**

This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or more of the following conditions, e.g., (1) primary vitamin D deficiency, (2) 1,25-(OH)2D3 deficiency, and (3) 1,25-(OH)2D3 resistance included within the syndrome of ARVDD.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT
(10) International Publication Number
WO 03/088976 A1

(51) International Patent Classification⁷: **A61K 31/59**,
C07C 401/00

(21) International Application Number: PCT/US03/12013

(22) International Filing Date: 17 April 2003 (17.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/127,005 19 April 2002 (19.04.2002) US

(71) Applicant (*for all designated States except US*): **BONE CARE INTERNATIONAL, INC.** [US/US]; 1600 Aspen Commons, Middleton, WI 53562 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MAZESS, Richard, B.** [US/US]; 3534 Blackhawk Drive, Madison, WI 53705 (US). **STRUGNELL, Stephen, A.** [CA/US]; 4917 Eyre Lane, Madison, WI 53711 (US). **KNUTSON, Joyce, C.** [US/US]; 24 North Prospect Avenue, Madison, WI 53726 (US).

(74) Agents: **WELCH, Teresa, J.** et al.; Michael Best & Friedrich LLP, One South Pinckney Street, P.O. Box 1806, Madison, WI 53701-1806 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*


Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM

(57) Abstract: This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or more of the following conditions, e.g., (1) primary vitamin D deficiency, (2) 1,25-(OH)2D3 deficiency, and (3) 1,25-(OH)2D3 resistance included within the syndrome of ARVDD.



WO 03/088976 A1

METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application is a continuation-in-part of U.S. Patent Application No. 09/501,093 filed February 9, 2000 which is a continuation-in-part of U.S. Patent Application No. 09/086,969, filed May 29, 1998 which is a continuation-in-part of U.S. Patent Application No. 08/907,659 filed August 8, 1997, now U.S. Patent No. 5,869,473, and this application is a continuation-in-part of U.S. Patent Application No. 08/907,660 filed August 8, 1997 which is a divisional of U.S. Patent Application No. 08/798,958, filed February 11, 1997, now U.S. Patent No. 5,707,980, which is a continuation of U.S. Patent Application No. 08/415,488, filed April 3, 1995, now U.S. Patent No. 5,602,116.

**STATEMENT REGARDING FEDERALLY SPONSORED
RESEARCH OR DEVELOPMENT**

[0002] Not Applicable.

BACKGROUND OF THE INVENTION

[0003] This invention relates to a method for treating or preventing hyperparathyroidism associated with aging by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The method also relates to treating or preventing hyperparathyroidism associated with Aging-Related Vitamin D Deficiency (ARVDD) syndrome. Included within the syndrome of ARVDD are one or more of the following conditions, (1) primary vitamin D deficiency, (2) 1,25-(OH)₂D₃ deficiency, and (3) 1,25-(OH)₂D₃ resistance due to decreased responsiveness of target organs. ARVDD typically produces elevated blood parathyroid hormone levels, i.e., hyperparathyroidism. The invention is also a method of treating one or more of the conditions included within the syndrome of ARVDD.

[0004] In general, there are a number of physiological changes that occur with aging. One such change is the serum parathyroid hormone (PTH) level which has been found to increase with age. The cause of this increase in PTH (which has been found to be as high as 50% greater at age 80 as compared to a basal level seen at age 30) is not entirely clear. It has been suggested that some form of vitamin D deficiency is likely implicated. [See, e.g., Lau, K.-H. W. and Baylink, D. J., *Calcif. Tissue Int.* 65:295-306

-2-

(1999); Pattanaungkul, S., et al., *J. Clinical Endocrinol. & Metab.* 85:11 4023-4027 (2000)]. Another change associated with aging is the decline in muscle strength. It has also been suggested that some form of vitamin D deficiency may be implicated. [Grady, D. et al., *J. Clin. Endocrinol. & Metab.* 73:1111-1117 (1991); Bischoff, H.A. et al., *Arch. Phys. Med. Rehabil.* 80:54-58 (1999); Theiler, R. et al., *Arch. Phys. Med. Rehabil.* 80:485-489 (1999); Bischoff, H.A. et al., *Histochem. J.* 33:19-24 (2001); Glerup, H. "Investigations on the role of vitamin D in muscle function," Ph.D. Thesis, Aarhus Bone and Mineral Research Group, University of Asrhus, Denmark (1999); Gulbrandsen, C.E. and Moss, R.L., U.S. Patent 5,350,745, issued September 27, 1994)]

[0005] Within the syndrome of ARVDD, there appear to be at least three different subtypes of vitamin D deficiency, each of which can occur with aging, and is characterized by an inadequate amount or insufficient biological action of 1,25-dihydroxyvitamin D₃. These subtypes of vitamin D deficiency include (1) primary vitamin D deficiency, i.e., inadequate supplies of the precursors, vitamin D and/or 25-hydroxyvitamin D₃ leading to insufficient production of 1,25-dihydroxyvitamin D₃; (2) 1,25-dihydroxyvitamin D₃ deficiency, i.e., reduced abilities of the kidney to produce 1,25-dihydroxyvitamin D₃; and (3) 1,25-dihydroxyvitamin D₃ resistance, i.e., reduced responsiveness of target organs to 1,25-dihydroxyvitamin D₃ actions. [See, e.g., Lau, K.-H. W. and Baylink, D. J., *Calcif. Tissue Int.* 65:295-306 (1999); Pattanaungkul, S et al., *J. Clinical Endocrinol. & Metab.* 85:11 4023-4027 (2000)].

[0006] Primary vitamin D deficiency is caused by an inadequate supply of precursors, i.e., vitamin D and/or 25-hydroxyvitamin D₃, resulting in low serum levels of 1,25-dihydroxyvitamin D₃. Vitamin D is supplied to the human body via photosynthesis in the skin as a response to the UV-B radiation of sunlight or it is obtained through dietary sources. Inadequate sunlight exposure, which is regularly seen in countries of northern latitudes [Heikinehimo, R et al., (1992) *Calcif Tissue Int* 51:105-110], or insufficient nutritional vitamin D intake, which is a common problem of the elderly [Toss, G et al., *Acta Med Scand* 208:87-89 (1980)], are frequent causes of primary vitamin D deficiency. The photosynthesized or absorbed vitamin D undergoes 25-hydroxylation to produce 25-dihydroxyvitamin D₃ in the liver. This hepatic hydroxylation is unregulated and solely substrate dependent. After production in the liver, 25-dihydroxyvitamin D₃ is converted to the physiologically active 1,25-

-3-

dihydroxyvitamin D₃ in the kidney by the renal 25-hydroxyvitamin D-1 α -hydroxylase. An inadequate vitamin D supply can lead to reduced levels of 25-hydroxyvitamin D₃, which then limits 1,25-dihydroxyvitamin D₃ production, resulting in low 1,25-dihydroxyvitamin D₃ levels, i.e., vitamin D deficiency [Ooms, ME et al., *J. Bone Miner Res.* 10:1177-1184 (1995)]. Thus, a low serum 25-dihydroxyvitamin D₃ level is a frequently used diagnostic hallmark for primary vitamin D deficiency. Primary vitamin D deficiency is not merely a biochemical abnormality; it is also associated with secondary hyperparathyroidism, increased bone turnover, bone loss, osteoporosis [*Id.*; Khaw, K.T. et al., *Br. Med. J.* 305:273-277 (1992)], and an increased risk of fractures [Eastell, R and Roggs, B.L., "Vitamin D and osteoporosis", Vitamin D, Feldman D, Glorieux FH, Pike JW (eds) Academic Press, San Diego, CA pp. 695-711 (1997); Chapuy, M.C. and Meunier, P.J., "Vitamin D insufficiency in adults and the elderly", Vitamin D, Feldman D, Glorieux FH, Pike JW (eds) Academic Press, San Diego, CA pp. 679-693 (1997); Lau, K.-H. W. and Baylink, D.J., *supra*].

[0007] 1,25-(OH)₂D₃ deficiency, unlike primary vitamin D deficiency, is not caused by a limitation of precursors, e.g., vitamin D and/or 25-dihydroxyvitamin D₃, but rather by a defect in the synthesis of 1,25-dihydroxyvitamin D₃. 1,25-dihydroxyvitamin D₃ deficiency causes a decrease in intestinal calcium absorption, increased serum PTH, increased bone resorption, bone loss, and osteoporosis. The pathogenesis of 1,25-dihydroxyvitamin D₃ deficiency is related to an impaired ability of the kidney to synthesize adequate amounts of 1,25-dihydroxyvitamin D₃ rather than an inadequate supply of the substrate 25-hydroxyvitamin D₃. 1,25-dihydroxyvitamin D₃ deficiency is common in patients with renal insufficiency, renal failure, or other renal diseases. Thus, low serum levels of 25-hydroxyvitamin D₃ are not characteristic of 1,25-dihydroxyvitamin D₃ deficiency. Low serum 1,25-dihydroxyvitamin D₃ levels, normal serum 25-hydroxyvitamin D₃ levels, calcium malabsorption, secondary hyperparathyroidism, increased bone turnover, and bone loss are diagnostic indicia of 1,25-dihydroxyvitamin D₃ deficiency. [See, Lau, K.-H. W. and Baylink, D.J., *supra*].

[0008] There is also evidence that 1,25(OH)₂D₃ resistance is present in the elderly. The aging-associated decline in functions of various tissues and organs in the elderly can produce resistance of target organs to 1,25-dihydroxyvitamin D₃, leading to reduced biological actions of the hormone. Higher levels of 1,25-dihydroxyvitamin D₃

-4-

are needed in patients with the 1,25-dihydroxyvitamin D₃ resistance to achieve the same levels of 1,25-dihydroxyvitamin D₃ hormonal actions as those seen in normal individuals. "Normal" 1,25-dihydroxyvitamin D₃ levels, which are adequate for normal subjects, are insufficient to meet the physiological needs of resistant patients. However, unlike 1,25-dihydroxyvitamin D₃ deficiency, which has a lower serum 1,25-dihydroxyvitamin D₃ level, 1,25-dihydroxyvitamin D₃ resistance would be expected to show normal or slightly elevated (due to feedback regulation) serum 1,25-dihydroxyvitamin D₃ levels. Yet, in spite of elevated levels of serum 1,25-dihydroxyvitamin D₃, these patients would exhibit all the metabolic features of vitamin D deficiency; i.e., reduced intestinal calcium absorption, secondary hyperparathyroidism, increased bone turnover, and bone loss. Consequently, a typical patient with 1,25-dihydroxyvitamin D₃ resistance would have normal serum 25-hydroxyvitamin D₃ levels, and normal or slightly elevated 1,25-dihydroxyvitamin D₃ serum levels, but at the same time would exhibit reduced intestinal calcium absorption, secondary hyperparathyroidism, increased bone resorption, bone loss, and osteoporosis. [See, Lau, K.-H. W. and Baylink, D.J., *supra*].

[0009] As noted herein above, serum PTH levels increase with age, and secondary hyperparathyroidism has been associated with aging. The disease of hyperparathyroidism is a generalized disorder resulting from excessive secretion of parathyroid hormone by one or more parathyroid glands. The disease is characterized by elevated blood parathyroid hormone levels and parathyroid glandular enlargement.

[0010] Hyperparathyroidism is subcategorized into primary, secondary and tertiary hyperparathyroidism. In primary hyperparathyroidism, the growth of the parathyroid glands is autonomous in nature, is usually due to tumors, e.g., parathyroid adenomas, and is presumably irreversible. Such adenomas typically do not exhibit vitamin D receptors and exhibit a resistivity to 1,25-dihydroxyvitamin D₃. In secondary hyperparathyroidism, associated, e.g., with 1,25-dihydroxyvitamin D₃ deficiency and/or resistance, the parathyroid gland hyperplasia is typically adaptive owing to resistance to the metabolic actions of the hormone, and is presumably reversible. Secondary hyperparathyroidism occurs in patients, e.g., with renal failure, osteomalacia, and intestinal malabsorption syndrome. Tertiary hyperparathyroidism is characterized by an autonomous proliferation state of the parathyroid glands with biological hyperfunction.

-5-

Tertiary hyperparathyroidism can occur in patients with secondary hyperparathyroidism, wherein the reversible hyperplasia associated with secondary hyperparathyroidism converts to an irreversible growth defect, the enlarged tissue having vitamin D receptors. In all forms of hyperparathyroidism, bone abnormalities, e.g., the loss of bone mass or decreased mineral content, are common and renal damage is possible. Hyperparathyroidism is thus also characterized by abnormal calcium, phosphorus and bone metabolism.

[0011] Historically, it has long been known that vitamin D plays a critical role regulating calcium metabolism. The discovery of the active forms of vitamin D in the 1970's [Holick, M. F. et al., *Proc. Natl. Acad. Sci. USA* 68, 803-804 (1971); Jones, G. et al., *Biochemistry* 14, 1250-1256 (1975)] and active vitamin D analogues [Holick, M. F. et al., *Science* 180, 190, 191 (1973); Lam, H. Y. et al., *Science* 186, 1038-1040 (1974)], caused much excitement and speculation about the usefulness of these compounds in the treatment of bone depletive disorders.

[0012] Animal and early clinical studies examining the effects of these active vitamin D compounds suggested that such agents would be useful in restoring calcium balance. However, the best indicator of the efficacy of vitamin D compounds to prevent or treat depletive bone disorders is bone itself (or, in the case of renal osteodystrophy, serum levels of parathyroid hormone (PTH)) rather than calcium absorption or calcium balance. Certain clinical studies with $1\alpha,25$ -dihydroxyvitamin D_3 , and 1α -hydroxyvitamin D_3 indicate that the ability of these agents to restore lost bone mass or bone mineral content is dose-related. [See, Ott, S. M. and Chesnut, C. H., *Annals of Int. Med.*; 110:267-274 (1989); Gallagher, J. C. et al., *Annals of Int. Med.*; 113:649-655 (1990); Aloia, J. et al., *Amer. J. Med.* 84:401-08 (1988); and Shiraki, M. et al., *Endocrinol. Japan* 32, 305-315 (1985)].

[0013] These clinical studies also indicate that at the dosage ranges required for these agents to be truly effective, toxicity in the form of hypercalcemia and hypercalciuria becomes a major problem. Attempts to increase the amount of $1\alpha,25$ -dihydroxyvitamin D_3 above 0.5 $\mu\text{g/day}$ have frequently resulted in toxicity. At dosage levels below 0.5 $\mu\text{g/day}$, clinically significant effects on bone are rarely observed. [See, Jensen, G. F. et al., *Clin. Endocrinol.* 16, 515-524 (1982); Christiansen, C. et al., *Eur. J.*

-6-

Clin. Invest. 11, 305-309 (1981)]. Doses of 2 µg/day of 1α-hydroxyvitamin D₃ (1α-(OH)D₃) were found to have efficacy in increasing bone mass in patients exhibiting senile osteoporosis [Sorensen, O. H. et al., *Clin. Endocrinol.* 7, 169S-175S (1977)]. Data from clinical studies in Japan, a population that has low calcium intake, indicate that efficacy is found with 1α-hydroxyvitamin D₃ when administered at 1 µg/day [Shiraki, M. et al., *Endocrinol. Japan.* 32:305-315 (1985); Orimo, H. et al., *Bone and Mineral* 3, 47-52 (1987)]. However, at 2 µg/day, toxicity with 1α-hydroxyvitamin D₃ occurs in approximately 67% of the patients, and at 1 µg/day this percentage is approximately 20%.

[0014] Thus, due to their toxicity, 1-hydroxylated vitamin D₃ compounds can only be administered at dosages that are, at best, modestly beneficial in preventing or treating loss of bone or bone mineral content. Indeed, Aloia et al., recommend that alternative routes of administration be sought that might avoid the toxicity problems and allow higher dosage levels to be achieved. [Aloia, J. et al., *Amer. J. Med.* 84:401-408 (1988)]. Despite reported toxicities of 1α-hydroxyvitamin D₃ and 1α,25-dihydroxyvitamin D₃, these two compounds remain the drugs of choice for treatment of many bone depletive diseases.

[0015] Both 1α-hydroxyvitamin D₃ and 1α,25-dihydroxyvitamin D₃ have been studied and are clinically used in certain countries in Asia and Europe to treat osteoporosis [Gillespie, W.J., et al., Abstract, *The Cochrane Library*, issue 2, 2001; DeChant, K.L. and Goa, K.L., *Drugs & Aging*, 5(4):300-317 (1994); Ikeda, K and Ogata, E., *Mechanisms of Aging & Development* 116:103-111 (2000); Tanizawa, T., *Osteoporos. Int.* 9:163-170 (1999); Civitelli, R., *Calcif. Tissue* 57:409-414 (1995); Parfitt, A.M., *Drugs* 36:513-520 (1988); Thompson, S.P. et al., *Brit. Edit. Soc. Bone Joint Surgery*, 72:1053-1056 (1990); Sairanen, S. et al., *Calcif. Tissue Int.* 67:122-127 (2000); Haas, H.G., *Horm. Metab. Res.* 11:168-171 (1979); Tilyard, M.W. et al., *New England J. Med.* 326:357-362 (1992); Aloia, J.F. et al., *Am. J. Med.* 84:401-408 (1988); Avioli, L., *Calcif. Tissue Int.* 65:2392-294 (1999); Orimi, H. et al., *Calcif. Tissue Int.* 54:370-376 (1994); Sorensen, O.H. et al., *Clinical Endocrinol.* 7 (Suppl.): 169S-175S (1997)] Some studies suggest that active vitamin D, such as 1α-hydroxyvitamin D₃ and 1α,25-dihydroxyvitamin D₃, appears to be more effective than precursors, e.g., vitamin

-7-

D, in treating, e.g., osteoporosis. These drugs appear to be most effective in those patients that have defective calcium absorption, e.g., in osteoporosis. Active vitamin D also appears to be more effective in treating $1\alpha,25$ -dihydroxyvitamin D₃ resistance in target organs, decline in responsiveness to PTH inducement of $1\alpha,25$ -dihydroxyvitamin D₃ synthesis, and lower production of $1\alpha,25$ -dihydroxyvitamin D₃ especially with aging. [Zerwekh, J.E. et al., *J. Clin. Endocrinol. Metab.* 56:410-413 (1983); Nordin, B.E.C. et al., *Calcif. Tissue Int.* 65:307-310 (1999); Morris, H.A. et al., *Calcif. Tissue Int.* 49:240-243 (1991); Shiraishi, A. et al., *Calcif. Tissue Int.* 65:311-316 (1999); Silverberg, S.J. et al., *New England J. Med.* 320(5):277-281 (1989); Francis, R.M., *Calcif. Tissue Int.* 60:111-114 (1997); Francis, R.M. et al., *Osteoporosis Int.* 6:284-290 (1996); Theiler, R. et al., *Int. J. Vit. Nur. Res.* 68:36-41 (1998)]

[0016] Also, as noted above, secondary hyperparathyroidism is a significant clinical problem associated with renal insufficiency and intestinal malabsorption syndromes, and has also been associated with aging as described herein above. As to renal failure, in the United States, end stage renal disease afflicts approximately 300,000 individuals. In this disease, there is a progressive loss of cells of the proximal nephrons, the primary site for the synthesis of the vitamin D hormones (collectively " $1\alpha,25$ -(OH)₂D") from 25-hydroxyvitamin D₃ and 25-hydroxyvitamin D₂. In addition, the loss of functioning nephrons leads to retention of excess phosphorus which reduces the activity of the renal 25-hydroxyvitamin D- 1α -hydroxylase, the enzyme which catalyzes the reaction to produce the D hormones. These two events account for the low serum levels of $1\alpha,25$ -(OH)₂D commonly found in patients with mild to moderate end stage renal disease.

[0017] Reduced serum levels of $1\alpha,25$ -(OH)₂D cause increased, and ultimately excessive, secretion of PTH by direct and indirect mechanisms. The resulting hyperparathyroidism leads to markedly increased bone turnover and its sequela of renal osteodystrophy, which may include a variety of other diseases, such as, osteitis fibrosa cystica, osteomalacia, osteoporosis, extraskeletal calcification and related disorders, e.g., bone pain, periarticular inflammation and Mockerberg's sclerosis. Reduced serum levels of $1\alpha,25$ -(OH)₂D also can cause muscle weakness and growth retardation with skeletal deformities (most often seen in pediatric patients).

-8-

[0018] Previous clinical studies of hormonally active vitamin D drugs in end stage renal disease patients, i.e., the treatment of secondary hyperthyroidism, have focused on compounds derived from vitamin D₃. 1 α ,25-(OH)₂D₃ and 1 α -(OH)D₃ are the major approved forms of 1 α -hydroxylated vitamin D for treatment or prevention, although these drugs are not currently approved in all major pharmaceutical markets. Use of 1 α ,25-(OH)₂D₃ and 1 α -(OH)D₃ as replacement therapy seeks to treat or prevent renal osteodystrophy by treating or preventing hyperparathyroidism in end stage renal disease patients. As noted above, 1 α ,25-(OH)₂D₃ often causes toxic side effects (hypercalcemia and hyperphosphatemia) at dosages above 0.5 μ g, especially when concomitantly administered phosphate binders, such as calcium compounds, are used to control serum phosphorus. The minimum effective dose for preventing hyperparathyroidism is in the range of 0.25 to 0.50 μ g/day; most patients respond to oral treatment doses of 0.5 to 1.0 μ g/day or intravenous doses between 0.5 and 3.0 μ g three times per week. As described above, the other commonly used vitamin D drug is 1 α -(OH)D₃ which often causes toxic effects at dosages over 1.0 μ g/day, especially when used with phosphate binders. The minimum effective dosage for preventing hyperparathyroidism is in the range of 0.25 to 1.0 μ g/day, and most patients require treatment dosages of 1.0 μ g/day or more. When either drug, 1 α ,25-(OH)₂D₃ or 1 α -(OH)D₃, is administered in higher dosages, both efficacy and toxicity are found to increase. Thus, the hormonally active vitamin D₃ compounds are limited in their therapeutic usefulness due to their inherent toxicities.

[0019] Attempts to reduce the toxic side effects of active vitamin D₃, in the renal failure setting have included administration of a low calcium dialysate with an ionized calcium concentration of 1.25 mM. However, it has been found that use of the low calcium dialysate has lead to higher serum PTH and phosphorus levels in patients who do not receive increased doses of oral calcium supplements and phosphate binders. When the dosages of calcium supplements and phosphate binders are increased, serum levels of phosphorus can be controlled, but the incidence of hypercalcemia rises markedly. Thus, there are many problems associated with the use of current vitamin D therapies for secondary hyperparathyroidism.

-9-

[0020] As to secondary hyperparathyroidism associated with aging, it has been suggested that treatment with 1α -OH-D₃ is advantageous over vitamin D. [Shiraishi, A et al., *Calcif. Tissue Int.* 65:292-294 (1999)]. However, although active forms of vitamin D₃ may have increased efficacy over precursors, their inherent toxicities still limit extensive therapeutic use.

[0021] Notwithstanding these known problems with use of the hormonally active vitamin D₃ for hyperparathyroidism, there is a need for vitamin D compounds, derivatives or analogs, and treatment protocols that have low inherent toxicity.

BRIEF DESCRIPTION OF THE INVENTION

[0022] In one aspect, the present invention provides a method of treating, i.e., ameliorating or preventing, hyperparathyroidism associated with aging. The method includes administering to a subject in need thereof an amount of an active vitamin D compound sufficient to lower elevated or maintain lowered blood parathyroid hormone (PTH) levels, i.e., sufficient to suppress parathyroid activity.

[0023] In another aspect, the invention provides a method of treating or preventing hyperparathyroidism associated with Aging-Related Vitamin D Deficiency (ARVDD) syndrome. The method includes administering an amount of an active vitamin D compound to a subject in need sufficient to lower elevated or maintain lowered blood parathyroid hormone levels. ARVDD includes one or more of primary vitamin D deficiency, $1,25$ -(OH)₂D₃ deficiency and $1,25$ -(OH)₂D₃ resistance. Thus, in a further aspect, the invention provides a method of treating or preventing one or more of the conditions associated with ARVDD.

[0024] The method further includes administration of the active vitamin D by a variety of effective treatment protocols. One such protocol includes intermittent or episodic high dose regimen of the active vitamin D compound. The active vitamin D compounds in accordance with the present invention have bioactivity equivalent to, but have lower toxicity than, conventional vitamin D therapies.

[0025] A fuller appreciation of the invention will be gained upon an examination of the following description, taken in conjunction with the appended claims.

-10-

BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Not Applicable.

DESCRIPTION OF THE INVENTION

[0027] The present invention relates to ameliorating or preventing hyperparathyroidism associated with aging and/or associated with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering an effective amount of an active vitamin D compound utilizing a variety of treatment protocols. ARVDD includes within the syndrome one or more of the following conditions, (1) primary vitamin D deficiency, (2) $1,25-(\text{OH})_2\text{D}_3$ deficiency, and (3) $1,25-(\text{OH})_2\text{D}_3$ resistance. An elevated blood parathyroid hormone level, i.e., hyperparathyroidism, is typically associated with aging and with one or more of the conditions within the syndrome of ARVDD. Accordingly, the present invention will now be described in detail with respect to such endeavors; however, those skilled in the art will appreciate that such a description of the invention is meant to be exemplary only and should not be viewed as limitative on the full scope thereof.

[0028] More specifically, the present invention relates to therapeutic methods for lowering elevated blood levels of parathyroid hormone (PTH) and/or maintaining lowered serum PTH levels associated with aging and/or ARVDD. The method is of value in ameliorating or preventing one or more of the conditions included within the syndrome of ARVDD by, e.g., minimizing vitamin D deficiency, increasing renal production of $1,25-(\text{OH})_2\text{D}_3$, and reducing $1,25-(\text{OH})_2\text{D}_3$ resistance in target organs. The method in accordance with the present invention has significantly less resultant hypercalcemia and hyperphosphatemia, especially in patients who use oral calcium as a phosphate binder to control serum phosphorus levels. Furthermore, the active vitamin D compounds when administered intermittently or episodically in a high dose regimen result in higher efficacy and reduced toxicity. These attributes are achieved through a novel method of treating patients suffering from hyperparathyroidism associated with aging and/or with one or more of the conditions associated with ARVDD.

[0029] As used herein, the term "Aging-Related Vitamin D Deficiency syndrome (ARVDD)" refers to one or more of the conditions of primary vitamin D deficiency, $1,25-(\text{OH})_2\text{D}_3$ deficiency and $1,25-(\text{OH})_2\text{D}_3$ resistance that can occur in the

-11-

elderly. In addition to poor sunlight exposure and decreased vitamin D intake, other factors that probably contribute to this ARVDD syndrome include defective renal production of $1,25\text{-(OH)}_2\text{D}_3$, and a progressive decrease in the number of the $1,25\text{-(OH)}_2\text{D}_3$ receptor (VDR) complexes which can transduce its biological effects on the intestine and bone.

[0030] Also, as used herein, the term "hyperparathyroidism" refers to primary, secondary and/or tertiary hyperparathyroidism.

[0031] It has been found that when the analogs of formula (I), described hereinbelow, are administered to patients with elevated serum parathyroid hormone, PTH concentration is lowered with significantly less hypercalcemia and hyperphosphatemia than is observed after the same amount of activated vitamin D_3 administered in previously known formulations and dosing regimens. Thus, the compounds of formula (I) have an improved therapeutic index relative to active vitamin D_3 analogs administered using conventional protocols.

[0032] It has been shown that 1α -hydroxyvitamin D_2 ($1\alpha\text{-(OH)D}_2$) has the same biopotency as 1α -hydroxyvitamin D_3 ($1\alpha\text{-(OH)D}_3$) and $1\alpha,25$ -dihydroxyvitamin D_3 ($1\alpha,25\text{-(OH)}_2\text{D}_3$) but is much less toxic [see, U.S. Patent 5,403,831 and U.S. Patent 5,104,864]. Even dosages up to $10\text{ }\mu\text{g/day}$ of $1\alpha\text{-(OH)D}_2$ in women with postmenopausal osteoporosis (in both open label and double blind testing) exhibited only mild hypercalciuria ($>300\text{ mg/24 hrs}$), and marked hypercalcemia ($>11.0\text{ mg/dL}$) solely due to $1\alpha\text{-(OH)D}_2$ was not evident. Additionally, $1\alpha\text{-(OH)D}_2$ did not adversely affect kidney function, as determined by creatinine clearance and BUN; nor did it increase urinary excretion of hydroxyproline, indicating the absence of any stimulatory effect on bone resorption. Administration of $1\alpha\text{-(OH)D}_2$ to healthy adult males in dosages up to $8\text{ }\mu\text{g/day}$ has shown no hypercalcemia or other adverse effects.

[0033] Furthermore, it is known that vitamin D_3 must be hydroxylated in the C-1 and C-25 positions before it is activated, i.e., before it will produce a biological response. A similar metabolism appears to be required to activate other forms of vitamin D, e.g., vitamin D_2 and vitamin D_4 . Therefore, as used herein, the term "activated vitamin D" or "active vitamin D" is intended to refer to a vitamin D compound or analog that has been

-12-

hydroxylated in at least one of the C-1, C-24 or C-25 positions of the molecule (i.e., a hydroxy vitamin D) and either the compound itself, or one of its metabolites in the case of a prodrug, binds to the vitamin D receptor (VDR). For example, vitamin D "prodrugs" include compounds that are hydroxylated in the C-1 position. Such compounds undergo further hydroxylation *in vivo* and their metabolites bind the VDR.


[0034] Also, as used herein, the term "lower" as a modifier for alkyl, alkenyl, acyl, or cycloalkyl is meant to refer to a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 4 carbon atoms. Specific examples of such hydrocarbon radicals are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *t*-butyl, ethenyl, propenyl, butenyl, isobutenyl, isopropenyl, formyl, acetyl, propionyl, butyryl or cyclopropyl. The term "aromatic acyl" is meant to refer to an unsubstituted or substituted benzyl group.

[0035] As used herein, the term "hydrocarbon moiety" refers to a lower alkyl, a lower alkenyl, a lower acyl group or a lower cycloalkyl, i.e., a straight or branched, saturated or unsaturated C₁-C₄ hydrocarbon radical.

[0036] Further, the active vitamin D in accordance with the present invention may have an unsaturated side chain, e.g., there is suitably a double bond between C-22 and C-23, between C-25 and C-26 or between C-26 and C-27.

[0037] An active vitamin D of the present invention i.e., a hydroxyvitamin D, has the general formula described in formula (I):

-13-




(I)

wherein A^1 and A^2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R^1 and R^2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R^1 and R^2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C_3 - C_8 cyclocarbon ring; R^3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X^1 is hydrogen or hydroxyl; X^2 is hydrogen or hydroxyl, or, may be taken with R^1 or R^2 , to constitute a double bond; and X^3 is hydrogen or hydroxyl provided that at least one of X^1 , X^2 and X^3 is hydroxyl.

[0038] Specific 1α -hydroxyvitamin D compounds in accordance with the present invention are characterized by the general formula (II):

-14-



wherein A^1 and A^2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R^1 and R^2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R^1 and R^2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C_3 - C_8 cyclocarbon ring; R^3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X^1 is hydrogen or hydroxyl; and X^2 is hydrogen or hydroxyl, or, may be taken with R^1 or R^2 , to constitute a double bond.

[0039] The active 1α -hydroxylated vitamin D analogs in accordance with the present invention wherein R^1 , R^2 , and R^3 are all methyl groups and X^2 is hydrogen, have the general formula (III):

(III)

[0040] Specific 24-hydroxyvitamin D compounds in accordance with the present invention are characterized by the general formula (IV):

Chemical structure (IV) is a complex molecule. It features a bicyclic system (a cyclohexane ring fused to a cyclopentane ring) connected via a vinyl group to a cyclohexane ring. This cyclohexane ring has a methyl group (CH₃) and a hydroxyl group (OH) attached. The side chain of the cyclohexane ring is a 1,2,3-trisubstituted butane chain. The substituents are: R¹ at the 1-position, R² at the 2-position, and R³ at the 3-position. The hydroxyl group (OH) is attached to the 2-position. The side chain is also substituted with A¹ and A² at the 1 and 2 positions, respectively. The side chain is also substituted with X² at the 3-position. The side chain is also substituted with X³ at the 4-position.

[0042] The compounds in accordance with the present invention are typically hypocalcemic compared to the natural D hormone, 1 α ,25-dihydroxyvitamin D₃.

-17-

“Hypocalcemic” is meant to refer to an active vitamin D compound that has reduced calcemic activity compared to that of the natural vitamin D hormone, $1\alpha,25$ -dihydroxyvitamin D_3 ; in other words, a calcemic index less than that of $1\alpha,25$ -dihydroxyvitamin D_3 . The calcemic activity of these compounds typically ranges from 0.001 to 0.5 that of $1\alpha,25$ -dihydroxyvitamin D_3 . “Calcemic index” is a relative measure of the ability of a drug to generate a calcemic response, the calcemic activity of $1\alpha,25$ -dihydroxyvitamin D_3 being designated as 1. Such hypocalcemia vitamin D compounds provide reduced risk of hypercalcemia even when administered in high doses.

[0043] Further, for compounds of formulas (I)-(IV) that have a chiral center; such as at the C-24 position, it is understood that both epimers (e.g., R and S) and the epimeric mixture are within the scope of the present invention. Where certain epimeric forms are preferred, the preferred form is substantially free of its other epimeric form, e.g., $1\alpha,24(S)$ -dihydroxyvitamin D_2 is preferably substantially free of its (R) epimer, and $1\alpha,24(R)$ -dihydroxy vitamin D_4 is preferred substantially free of its (S) epimer.

[0044] The vitamin D analogs of formulas (I)-(IV) are useful as active compounds in pharmaceutical compositions. The active vitamin D compounds of the present invention include vitamin D compounds having a hydroxy group substituted in at least one of the C_1 , C_{24} or C_{25} positions of the molecule, i.e., a hydroxy vitamin D. The analogs of formula (III) are of especial value as they are substantially less toxic than their vitamin D_3 counterparts when administered by conventional protocols to patients experiencing hyperparathyroidism. For example, in patients using oral calcium as a phosphate binder, e.g., calcium carbonate or calcium acetate, administration of the analogs of formula (III) at dosage levels higher than possible with the vitamin D_3 compounds provides greater efficacy than heretofore possible in treating hyperparathyroidism.

[0045] Effective amounts of active vitamin D compounds in accordance with the present invention may be administered on a daily or episodic basis. Dosages may be from 1 μg to 150 μg per week given daily or 10 $\mu\text{g}/\text{dose}$ or greater up to 200 $\mu\text{g}/\text{dose}$ or greater, given episodically or intermittently.

-18-

[0046] The method in accordance with the present invention also includes use of active vitamin D compounds, and of particular value, hypocalcemic active vitamin D compounds, especially compounds of vitamins D₂, D₃ and D₄, in high dosage form, administered on an intermittent or episodic basis, to treat hyperparathyroidism associated with aging and inhibit symptoms associated with ARVDD syndrome. The active vitamin D compounds given in episodic or intermittent high dose may also be co-administered with other therapeutic agents (as described in detail below). Administration of the active vitamin D may be prior to, simultaneous with, or after administration of the other therapeutic agents.

[0047] With the episodic or intermittent dosing protocol in accordance with the present, high dose amounts administered to patients having ARVDD may even include 1 α ,25-dihydroxyvitamin D₃ (calcitriol), or 1 α -(OH)-D₃ (alphacalcidol). By "high dose" is meant a dose of 10 μ g or more, e.g., 20 μ g to 100 μ g or more, e.g. 300 μ g. In other terms, a "high dose" is one that produces higher than normal physiologic levels of vitamin D *in vivo*, or is sufficient in a single dose to upregulate vitamin D receptors on cells expressing these receptors. The intermittent dosing regimen is suitably between once per week to once every 12 weeks, e.g., once every 3 weeks. As a function of body weight, the effective dose ranges from about 0.2 μ g to about 4.5 μ g per kilogram of body weight of the patient.

[0048] The episodic protocol or dosage regimen in accordance with the present invention provides an improved therapeutic index for active forms of vitamin D analogues compared to administration via conventional regimens. The episodic dosing is also cost effective, as less active agent is needed.

[0049] It is further believed that the intermittent high dose regimen can be used to effect any therapeutic effect that is attributable to active vitamin D., e.g., reduction of loss of bone mass, etc. The value of the intermittent dosing is that upregulation of vitamin D receptors occurs with a single dose without the side effects of hypercalcemia and hypercalciuria that occur with recurrent daily dosing.

[0050] The episodic dose can be a single dose or, optionally, divided into 2-4 subdoses which, if desired, can be given, e.g., twenty minutes to an hour apart until the

-19-

total dose is given. The compounds in accordance with the present invention are administered in an amount that raises serum vitamin D levels to a supraphysiological level for a sufficient period of time to alleviate, e.g., 1,25-(OH)₂D₃ deficiency and/or resistance without causing hypercalcemia or with substantially reduced the risk of hypercalcemia. The properties of the hypocalcemic vitamin D compounds in accordance with the present invention are particularly beneficial in permitting such supraphysiologic levels.

[0051] Generally, the pharmacologically active compounds of the present invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. For example, the active vitamin D compounds of the present invention can be formulated in pharmaceutical compositions in a conventional manner using one or more conventional excipients, which do not deleteriously react with the active compounds, e.g., pharmaceutically acceptable carrier substances suitable for enteral administration (e.g., oral), parenteral, topical, buccal or rectal application, or by administration by inhalation or insufflation (e.g., either through the mouth or the nose)

[0052] Generally, acceptable carriers for pharmaceutical formulation include, but are not limited to, water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., almond oil, corn oil, cottonseed oil, peanut oil, olive oil, coconut oil), mineral oil, fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatin, carbohydrates (e.g., lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinylpyrrolidone, etc.

[0053] Of particular interest is the parenteral, e.g., injectable, dosage form. Using the parenteral route of administration allows for bypass of the first pass of active vitamin D compound through the intestine, thus avoiding stimulation of intestinal calcium absorption, and further, reduces the risk of esophageal irritation which may be associated with high dose oral administration. Because an injectable route of administration is typically done by a health care professional, the dosing can be more effectively controlled as to precise amount and timing. Parenteral administration suitably

-20-

includes subcutaneous, intramuscular, or intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption.

[0054] Injectable compositions may take such forms as sterile suspensions, solutions, or emulsions in oily vehicles (such as coconut oil, cottonseed oil, sesame oil, peanut oil or soybean oil) or aqueous vehicles, and may contain various formulating agents. Alternatively, the active ingredient may be in powder (lyophilized or non-lyophilized) form for reconstitution at the time of delivery with a suitable vehicle, such as sterile water.

[0055] In injectable compositions, the carrier is typically sterile and pyrogen-free, e.g., water, saline, aqueous propylene glycol, or another injectable liquid, e.g., peanut oil for intramuscular injections. Also, various buffering agents, preservatives, suspending, stabilizing or dispensing agents, surface-active agents and the like can be included. Aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. Aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well known to those skilled in the art. The oily solutions are especially suitable for intra-articular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

[0056] The compounds in accordance with the present invention formulated for parenteral administration by injection may be administered by bolus injection or continuous infusion. Formulations for injection may be conveniently presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.

[0057] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an

-21-

acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., a sparingly soluble salt.

[0058] For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. Syrup, elixir, or the like can be used if a sweetened vehicle is desired. For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules, e.g., soft or hard gel capsules; prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). Tablets may be coated by methods well known in the art.

[0059] Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

[0060] Preparations for oral administration may also be suitably formulated to give controlled release of the active compound. Many controlled release systems are known in the art.

[0061] For buccal administration, the compositions may take the form of tablets, lozenges or absorption wafers formulated in conventional manner.

[0062] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon

-22-

dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin, for use in an inhaler or insufflator may be formulated containing a powder mix of the active compound and a suitable powder base such as lactose or starch.

[0063] The compounds may also be formulated in rectal or vaginal compositions, such as suppositories containing conventional suppository bases or retention enemas. These compositions can be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at room temperature (for example, 10° C to 32° C) but liquid at the rectal temperature, and will melt in the rectum or vagina to release the active ingredient. Such materials are polyethylene glycols, cocoa butter, other glycerides and wax. To prolong storage life, the compositions advantageously may include an antioxidant such as ascorbic acid, butylated hydroxyanisole or hydroquinone.

[0064] The compositions may, if desired, be presented in a pack or dispenser device that may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device is suitably accompanied by instructions for administration.

[0065] For topical application, suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water, for example, mineral oil, almond oil, self-emulsifying beeswax, vegetable oil, white soft paraffin, and propylene glycol. Suitable formulations include, but are not limited to, creams, jellies, gels, pastes, ointments, lotions, solutions, suspensions, emulsions, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, demulsifiers, wetting agents, etc. A cream preparation in accordance with the present invention suitably includes, for example, mixture of water, almond oil, mineral oil and self-emulsifying beeswax; an ointment preparation suitably includes, for example, almond oil and white soft paraffin; and a lotion preparation suitably includes, for example, dry propylene glycol. For purposes of transdermal administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, are prepared.

-23-

[0066] Those of ordinary skill in the art will readily optimize effective doses and co-administration regimens (as described hereinbelow) as determined by good medical practice and the clinical condition of the individual patient. Regardless of the manner of administration, it will be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. For example, the specific dose for a particular patient depends on age, sex, body weight, general state of health, on diet, on the timing and mode of administration, on the rate of excretion, and on medicaments used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given patient can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol. A physician of ordinary skill can readily determine and prescribe the effective amount of the drug required to counter or arrest the progress of the condition. Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that an efficacious dosage is obtained. The active ingredient is administered to patients (animal and human) in need of treatment in dosages that will provide optimal pharmaceutical efficacy.

[0067] Also included within the scope of the present invention is the co-administration of effective dosages of the analogs of formulas (I)-(IV) in conjunction with hormones or other therapeutic agents, e.g., estrogens, which are known to ameliorate bone diseases or disorders typically associated with hyperparathyroidism and ARVDD syndrome. Such bone agents may include other vitamin D compounds, conjugated estrogens or their equivalents, calcitonin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin and boron.

[0068] The term "co-administration" is meant to refer to a combination therapy by any administration route in which two or more agents are administered to a patient or

-24-

subject. Co-administration of agents may be referred to as combination therapy or combination treatment. The agents may be in the same dosage formulations or separate formulations. For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents can be administered concurrently, or they each can be administered at separately staggered times. The agents may be administered simultaneously or sequentially (i.e., one agent may directly follow administration of the other or the agents may be give episodically, i.e., one can be given at one time followed by the other at a later time, e.g., within a week), as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations in the body. The agents may also be administered by different routes, e.g., one agent may be administered intravenously while a second agent is administered intramuscularly, intravenously or orally. In other words, the co-administration of the active vitamin D compound in accordance with the present invention with another therapeutic agent is suitably considered a combined pharmaceutical preparation which contains an active vitamin D compound and, e.g., a bone agent, the preparation being adapted for the administration of the active vitamin D compound on a daily or intermittent basis, and the administration of, e.g., a bone agent on a daily or intermittent basis. The agents also may be formulated as an admixture, as, for example, in a single tablet.

[0069] Possible dose ranges for exemplary co-administered agents are provided in Table 1.

-25-

TABLE 1

Possible Oral Dose Ranges for Various Agents Co-Administered With Active Vitamin D Compounds of Formulas (I)-(IV)			
Agent	Dose Ranges		
	Broad	Preferred	Most Preferred
Conjugated Estrogens or Equivalent (mg/day)	0.3-5.0	0.4-2.4	0.6-1.2
Sodium Fluoride (mg/day)	5-150	30-75	40-60
Calcitonin (IU/day)	5-800	25-500	50-200
Bisphosphonates (mg/day)	50-2000	100-1500	250-1000
Calcium Supplements (mg/day)	250-2500	500-1500	750-1000
Cobalamin (µg/day)	5-200	20-100	30-50
Pertussis Toxin (mg/day)	0.1-2000	10-1500	100-1000
Boron (mg/day)	0.10-3000	1-250	2-100

[0070] Although the above dosages are for oral administration, it is understood that the co-administered agents can also be administered in alternative fashions, including intranasally, transdermally,¹ intrarectally, intravaginally, subcutaneously, intravenously, and intramuscularly. It is also contemplated that some of the co-administered agents may be given on an other than daily basis.

[0071] For convenience, the active vitamin D compound in accordance with the present invention and the co-administered therapeutic agent may be packaged together, e.g., in a blister pack or dispenser device. In other words, the active vitamin D compound and the other therapeutic agent may be contained in a common package, each contained in a separate container therein, and also having instructions for use of the compound and agent in the treatment of hyperparathyroidism, e.g., instructions for administering the active vitamin D compound and the therapeutic agent to a subject having hyperparathyroidism and/or suffering from ARVDD on a daily or episodic basis.

[0072] Bulk quantities of the vitamin D analogs in accordance with the present invention can be readily obtained in accordance with the many widely known processes, e.g., as described in U.S. Patents Nos. 3,907,843; 4,195,027; 4,202,829; 4,234,495; 4,260,549; 4,555,364; 4,554,106; 4,670,190; and 5,488,120; WO 94/05630, and

-26-

Strugnell *et al.*, 310 *Biochem. J.* 233-241 (1995), all of which are herein fully incorporated by reference.

[0073] The present invention is further explained by the following examples, which should not be construed by way of limiting the scope of the present invention.

EXAMPLES

Comparison of 1 α -OH-vitamin D₂ with 1 α -OH-vitamin D₃

[0074] A comparison of 1 α -(OH)D₂ to 1 α -(OH)D₃ has been conducted. 1 α -(OH)D₂ is equally active as 1 α -(OH)D₃ in the healing of rickets, in the stimulation of intestinal calcium absorption and in the elevation of serum inorganic phosphorous of rachitic rats. [G. Sjoden *et al.*, *J. Nutr.* 114, 2043-2946 (1984)]. In the same laboratory animal, 1 α -OH-D₂ was found to be 5 to 15 times less toxic than 1 α -OH-D₃ [see, also, G. Sjoden *et al.*, *Proc. Soc. Exp. Biol. Med.* 178, 432-436 (1985)]. It has also now been found that, for example, 1 α -OH-D₂ may be safely administered for up to two years to human subjects experiencing or having a tendency toward loss of bone mass or bone mineral content at dosages greater than 3 μ g/day.

[0075] The following examples demonstrate that 1 α -(OH)D₂ and 1 α ,24-(OH)₂D₄ are effective in reducing or preventing elevated blood PTH levels as well as preventing or restoring the loss of bone mass or bone mineral content while being substantially less toxic than 1 α ,25-(OH)₂D₃ and 1 α -(OH)D₃. It is to be understood that although the following examples detail the use of 1 α -(OH)D₂ and 1 α ,24-(OH)₂D₄, 1 α ,24(S)-(OH)₂D₂ may be readily utilized in the treatment of this invention with essentially equivalent results. For example, 1 α ,24(S)-(OH)₂D₂ shows activity equivalent to 1 α ,24(R)-(OH)₂D₃ and is also significantly less toxic than its vitamin D₃ counterpart.

Example 1: Study Demonstrating Better Safety

[0076] The low toxicity of 1 α -(OH)D₂ in human patients was demonstrated in a clinical study involving 15 postmenopausal osteoporotic women. [*J. Bone Min. Res.*; 9:607-614 (1994).] The selected patients were between 55 and 75 years of age, and exhibited L2-L3 vertebral bone mineral density ("BMD") between 0.7 and 1.05 g/cm², as determined by measurements with a LUNAR dual-photon absorptiometer. (The mean

-27-

bone mineral density in women with osteoporosis is about $0.85 \pm 0.17 \text{ g/cm}^2$, so that these limits correspond to about the 15th to 85th percentiles.)

[0077] On admission to the study, all patients received instruction on selecting a daily diet containing 400 to 600 mg of calcium. Compliance to this diet was verified at weekly intervals by 24-hour food records and by interviews with each patient.

[0078] All patients completed a one-week baseline period, a five- to seven-week treatment period, and a one-week post-treatment observation period. During the treatment period, patients orally self-administered $1\alpha\text{-(OH)D}_2$ at an initial dose of $0.5 \mu\text{g/day}$ for the first week, and at successively higher doses of 1.0, 2.0, 4.0, 5.0, 8.0 and $10.0 \mu\text{g/day}$ in each of the following weeks. All doses were administered before breakfast.

[0079] Blood and urine chemistries were monitored on a weekly basis throughout the study. Key blood chemistries included fasting serum levels of calcium, phosphorus, osteocalcin, creatinine and blood urea nitrogen. Key urine chemistries included 24-hour excretion of calcium, phosphorus and creatinine.

[0080] Data from the study clearly demonstrated that $1\alpha\text{-(OH)D}_2$ can be safely administered at high dose levels on a daily dosing regimen for periods of several weeks. In particular, the compound did not adversely affect kidney function, as determined by creatinine clearance and blood levels of urea nitrogen; nor did it increase urinary excretion of hydroxyproline, indicating the absence of any stimulatory effect on bone resorption. The compound had no effect on any routinely monitored serum chemistries, indicating the absence of adverse metabolic effects.

[0081] A positive effect of $1\alpha\text{-(OH)D}_2$ on calcium homeostasis was evident from dose-related increases observed in 24-hour urinary calcium levels, confirming that the compound increases intestinal calcium absorption, and from dose-related increases in serum osteocalcin, suggesting that the compound directly stimulates bone formation.

-28-

Example 2: Study Demonstrating Safety and Efficacy for Human Osteoporosis

[0082] The safety and efficacy of 1α -(OH) D_2 as an oral treatment for osteoporosis was confirmed in a study involving 60 postmenopausal osteoporotic outpatients. The selected subjects had ages between 60 and 70 years, and exhibited L2-L3 vertebral BMD between 0.7 and 1.05 g/cm², as determined by dual-energy x-ray absorptiometry (DEXA). Exclusion criteria encompassed significant medical disorders and recent use of medications known to affect bone or calcium metabolism.

[0083] On admission to the study, each subject was assigned at random to one of two treatment groups; one group received up to a 104-week course of therapy with 1α -(OH) D_2 ; the other received only placebo therapy. All subjects received instruction on selecting a daily diet containing 700-900 mg of calcium and were advised to adhere to this diet over the course of the study. Compliance to the diet was verified at regular intervals by 24-hour food records and by interviews with each subject.

[0084] During the treatment period, subjects from one group orally self-administered 1α -(OH) D_2 at an initial dosage of 1.0 μ g/day for one week, and increased the dosage to 2.0, 3.0, 4.0 μ g/day in each of the following weeks, to a maximum dosage of 5.0 μ g/day. The dosage for any given subject was increased in this way until the rate of urinary calcium excretion was elevated to approximately 275-300 mg/24 hours, at which point the subject held the dosage constant at the highest level attained. Subjects from the second group self-administered a matching placebo medication every day, titrating the apparent dosage upwards in the same manner as subjects being treated with 1α -(OH) D_2 .

[0085] Spinal and femoral neck BMD were measured in all subjects by DEXA at the beginning of the study, and at six-month intervals thereafter. Intestinal calcium absorption was estimated in all subjects by a single isotope technique at the beginning of the study, and at 12-month intervals. Serum levels of vitamin D metabolites were determined by radioreceptor binding assays at baseline and at six-month intervals. Serum osteocalcin, serum PTH and urine hydroxyproline also were determined at baseline and at six-month intervals.

-29-

[0086] Other blood and urine chemistries were monitored at regular intervals during the treatment period. These chemistries included serum calcium, serum ionized calcium, urine calcium, blood urea nitrogen, serum creatinine and creatinine clearance. Kidney-ureter-bladder (KUB) x-rays were obtained at baseline and at 12-month intervals thereafter.

[0087] The results of the study are summarized below:

[0088] Subjects: Sixty subjects enrolled in what was originally intended to be a 52-week study. Of these 60 subjects, 55 completed one year of treatment (28 active; 27 placebo); and 41 subjects completed an optional second year of treatment.

[0089] Test Drug Dosages: The average prescribed dosage for subjects who received 1α -(OH) D_2 was 4.2 μ g/day at 52 weeks and 3.6 μ g/day at 104 weeks. The average prescribed dosage for placebo subjects was an apparent 4.8 μ g/day at 52 weeks and 4.8 μ g/day at 104 weeks.

[0090] Exclusions: One subject failed to comply with the prescribed dosage of test drug, as confirmed by an absence of serum $1\alpha,25$ -(OH) $_2D_2$ at any time during the study. Data for this subject were excluded from analysis. Three patients were diagnosed with hyperparathyroidism when the PTH assays were completed (in batch) at the study's conclusion; data for these subjects were excluded from analysis. No subjects were excluded from analysis for noncompliance with the required dietary calcium intake of 700-900 mg/day.

[0091] Episodes of Hypercalcemia/Hypercalciuria: Marked hypercalcemia (>10.8 mg/dL) occurred in one subject in association with an intercurrent illness. The prescribed dosage of 1α -(OH) D_2 at the time of this episode was 5.0 μ g/day. Moderate hypercalcemia (10.4-10.8 mg/dL) occurred in two subjects over the course of the study at prescribed dosages of 5.0 μ g/day. Mild hypercalcemia (10.2-10.4 mg/dL) occurred in four subjects in the first year and in two subjects in the second year. Hypercalciuria was observed occasionally over the two-year study in 17 subjects treated with 1α -(OH) D_2 .

[0092] Serum Calcium/Ionized Calcium: Mean serum calcium was approximately 0.1 to 0.2 mg/dL higher in subjects treated with 1α -(OH) D_2 than in

-30-

subjects treated with placebo. This difference was significant ($P < 0.05$) only during the second year of treatment. Mean serum ionized calcium was approximately 0.05 to 0.10 mg/dL higher in subjects treated with 1α -(OH) D_2 .

[0093] Urine Calcium: Mean urine calcium increased during the initial titration period in a dose-response fashion. After titration, mean urine calcium was 50 to 130% higher ($P < 0.001$) with 1α -(OH) D_2 treatment than with placebo treatment.

[0094] Kidney Function: No significant changes were observed with long-term 1α -(OH) D_2 treatment in BUN, serum creatinine or creatinine clearance. KUB x-rays revealed no abnormalities in either treatment group throughout the course of the study.

[0095] Bone: Bone mineral density (BMD) in the L2-L4 vertebrae progressively increased with 1α -(OH) D_2 treatment and decreased with placebo treatment over the two-year study. The difference in spinal BMD between the treatment groups became statistically significant ($P < 0.05$) after 24 months of treatment. Similar changes were observed in femoral neck BMD with statistically significant differences observed after 18 months ($P < 0.001$) and 24 months ($P < 0.05$) of treatment.

[0096] Calcium Uptake: Intestinal absorption of orally administered ^{45}Ca increased by 40% ($P < 0.001$) after 52 weeks of 1α -(OH) D_2 therapy, and by 29% ($P < 0.5$) after 104 weeks of 1α -(OH) D_2 therapy, relative to placebo control.

[0097] Vitamin D Metabolites: Treatment with 1α -(OH) D_2 caused progressive increases in mean serum total $1\alpha,25$ -(OH) $_2D_3$ from 21% ($P < 0.05$) at six months to 49% ($P < 0.01$) at 24 months relative to placebo therapy. This increase resulted from a dramatic rise in serum $1\alpha,25$ -(OH) $_2D_2$ which was partially offset by a 50+ % decrease in serum $1\alpha,25$ -(OH) $_2D_3$. No treatment related changes were apparent in serum total 25-(OH)D.

-31-

[0098] Biochemical Parameters:

[0099] Serum levels of PTH decreased with 1α -(OH) D_2 therapy by 17% at 52 weeks and by 25% at 1-4 weeks, relative to placebo therapy.

[00100] Serum levels of osteocalcin were unchanged with long-term 1α -(OH) D_2 therapy.

[00101] Fasting urine hydroxyproline:creatinine ratio tended to decrease with long-term 1α -(OH) D_2 treatment but the observed differences between the 1α -(OH) D_2 and placebo treatment groups were not significantly different.

[00102] The results of this study clearly indicated that 1α -(OH) D_2 can be tolerated in higher long-term daily dosages than the commonly used vitamin D_3 analogues. They also showed that 1α -(OH) D_2 is well tolerated in postmenopausal women at long-term dosages in the range of 2.0 to 3.0 μ g/day, provided that individuals exhibiting abnormally high urine calcium levels (when not receiving vitamin D therapy) are excluded from treatment. Long-term administration of such high dosages of 1α -(OH) D_2 significantly reduced bone loss at the spine and femoral neck, the most frequent sites of osteoporotic fractures. These positive effects on bone were accompanied by a sustained increase in intestinal calcium absorption and a sustained decrease in serum PTH. They were not accompanied by clear long-term trends in serum osteocalcin and urine hydroxyproline. Taken together, the results of this study demonstrate that 1α -(OH) D_2 is safe and effective in the treatment of postmenopausal or senile osteoporosis.

Secondary Hyperparathyroidism Studies

Example 3: Open Label Study in End Stage Renal Disease Patients Exhibiting Secondary Hyperparathyroidism

[00103] Five end stage renal disease patients were enrolled in an open label study. The selected patients had ages between 36 and 72 years and had been on hemodialysis for at least 4 months prior to enrollment. The patients each had an average serum phosphorus in the range of 3.0 to less than or equal to 6.9 mg/dL during the two months prior to enrollment (often controlled by oral calcium as a phosphate binder e.g., calcium

-32-

carbonate or calcium acetate), and had a history of elevated serum PTH values of greater than 400 pg/mL when not receiving $1\alpha,25\text{-(OH)}_2\text{D}_3$ therapy.

[00104] Each patient had been receiving $1\alpha,25\text{-(OH)}_2\text{D}_3$ prior to enrollment, and discontinued the $1\alpha,25\text{-(OH)}_2\text{D}_3$ therapy for eight weeks prior to receiving $1\alpha\text{-(OH)D}_2$. After 8 weeks, the patients received treatment of $1\alpha\text{-(OH)D}_2$ at a dosage of 4 $\mu\text{g/day}$ for 6 weeks. Throughout the eight-week washout period and the treatment period, patients were monitored weekly or biweekly for serum intact PTH level and weekly for excessive elevation in serum levels of calcium and phosphorus.

[00105] Throughout the washout period and treatment period, patients underwent routine hemodialysis (3 times per week) using a 1.25 mM calcium dialysate. They also ingested significant amounts of calcium as phosphate binders (1-10g elemental Ca) to keep serum phosphorus levels below 6.9 mg/dL.

[00106] Average baseline values were as follows: serum PTH - 480 ± 21 pg/mL; serum Ca - 8 ± 0.3 mg/mL and serum phosphorus - 5.1 ± 0.2 mg/mL. In three patients, serum PTH decreased by 68%, 74% and 87% after two weeks. In the other two patients, serum PTH declined by 33% in one and 3% in the other after four weeks. Overall, serum PTH decreased by $49 \pm 17\%$ and $33 \pm 9\%$ after two and four weeks of $1\alpha\text{-OH-D}_2$, respectively, ($p < 0.05$). Serum calcium (mg/dL) was 10.2 ± 0.4 ($p < 0.05$) and 9.8 ± 0.2 (NS) and serum phosphorus (mg/dL) was 5.4 ± 0.5 and 5.5 ± 0.8 at two and four weeks, respectively (NS). A rise in serum PTH from the second to fourth weeks of $1\alpha\text{-(OH)D}_2$ treatment occurred when $1\alpha\text{-(OH)D}_2$ was withheld in three patients with serum PTH < 130; they developed mild hypercalcemia (serum calcium, 10.3-11.4 mg/dL) that reversed after stopping $1\alpha\text{-(OH)D}_2$. No other adverse effects occurred. At 4-6 weeks of $1\alpha\text{-(OH)D}_2$ treatment of 4 μg , thrice weekly, four of five patients were in the target range of serum PTH; serum calcium was 10.0 ± 0.2 mg/dL and serum phosphorus, 5.3 ± 0.2 mg/dL. The patient who failed to respond to six weeks of $1\alpha\text{-(OH)D}_2$ treatment had a delayed response to both intravenous and oral calcitriol earlier, requiring several months of treatment before serum PTH fell. Serum PTH values in this patient fell by 38% after eight weeks of $1\alpha\text{-(OH)D}_2$ treatment. These data show that $1\alpha\text{-(OH)D}_2$ is efficacious and safe for the control of secondary hyperparathyroidism in end stage renal disease patients.

-33-

Example 4: Double Blind Study of Bone in End Stage Renal Disease Patients

[00107] A twelve-month double-blind placebo-controlled clinical trial is conducted with thirty-five men and women with renal disease who are undergoing chronic hemodialysis. All patients enter an eight-week control period during which time they receive a maintenance dose of vitamin D₃ (400 IU/day). After this control period, the patients are randomized into two treatment groups: one group receives a constant dosage of 1 α -(OH)D₂ (u.i.d.; a dosage greater than 3.0 μ g/day) and the other group receives a matching placebo. Both treatment groups receive a maintenance dosage of vitamin D₃, maintain a normal intake of dietary calcium, and refrain from using calcium supplements. Oral calcium phosphate binders are used as necessary to maintain serum levels of phosphorus below 7.0 mg/dL. Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a) direct measurements of intestinal calcium absorption, (b) total body calcium retention, (c) radial and spinal bone mineral density, and (d) determinations of serum calcium and osteocalcin. Safety is evaluated by regular monitoring of serum calcium.

[00108] Analysis of the clinical data show that 1 α -(OH)D₂ significantly increases serum osteocalcin levels and intestinal calcium absorption, as determined by direct measurement using a double-isotope technique. Patients treated with 1 α -(OH)D₂ show normalized serum calcium levels, stable values for total body calcium, and stable radial and spinal bone densities relative to baseline values. In contrast, patients treated with placebo show frequent hypocalcemia, significant reductions in total body calcium and radial and spinal bone density. An insignificant incidence of hypercalcemia is observed in the treated group.

Example 5: Double-blind Study in End Stage Renal Disease (ESRD) Patients Exhibiting Secondary Hyperparathyroidism

[00109] Up to 120 ESRD (End Stage Renal Disease) patients undergoing chronic hemodialysis are studied in a multicenter, double-blind, placebo-controlled study. The selected patients reside in two major metropolitan areas within the continental U.S., have ages between 20 and 75 years and have a history of secondary hyperparathyroidism. They have been on hemodialysis for at least four months, have a normal (or near normal)

-34-

serum albumin, and have controlled serum phosphorus (often by using oral calcium phosphate binders).

[00110] On admission to the study, each patient is assigned at random to one of two treatment groups. One of these groups receives two consecutive 12-week courses of therapy with 1α -(OH) D_2 ; the other receives a 12-week course of therapy with 1α -(OH) D_2 followed, without interruption, by a 12-week course of placebo therapy. Each patient discontinues any $1\alpha,25$ -(OH) $_2D_3$ therapy for eight weeks prior to initiating 1α -(OH) D_2 therapy (4 μ g/day). Throughout this eight-week washout (or control) period and the two subsequent 12-week treatment periods, patients are monitored weekly for serum calcium and phosphorus. Serum intact PTH is monitored weekly or biweekly, and bone-specific serum markers, serum vitamin D metabolites, serum albumin, blood chemistries, hemoglobin and hematocrit are monitored at selected intervals.

[00111] During the study, patients undergo routine hemodialysis (three times per week) using a 1.24 mM calcium dialysate and ingest calcium phosphate binders (such as calcium carbonate or calcium acetate) in an amount sufficient to keep serum phosphate controlled (6.9 mg/dL). Patients who develop persistent mild hypercalcemia or mild hyperphosphatemia during the treatment periods reduce their 1α -(OH) D_2 dosage to 4 μ g three times per week (or lower). Patients who develop marked hypercalcemia or marked hyperphosphatemia immediately suspend treatment. Such patients are monitored at twice weekly intervals until the serum calcium or phosphorus is normalized, and resume 1α -(OH) D_2 dosing at a rate which is 4 μ g three times per week (or lower).

[00112] During the eight-week washout period, the mean serum level of PTH increases progressively and significantly. After initiation of 1α -(OH) D_2 dosing, mean serum PTH decreases significantly to less than 50% of pretreatment levels. Due to this drop in serum PTH, some patients need to reduce their dosage of 1α -(OH) D_2 to 4 μ g three times per week (or to even lower levels) to prevent excessive suppression of serum PTH. In such patients, exhibiting excessive suppression of serum PTH, transient mild hypercalcemia is observed, which is corrected by appropriate reductions in 1α -(OH) D_2 dosages.

-35-

[00113] At the end of the first 12-week treatment period, mean serum PTH is in the desired range of 130 to 240 pg/mL and serum levels of calcium and phosphorus are normal or near normal for end stage renal disease patients. For the placebo group, at the end of the second 12-week treatment period (during which time 1α -(OH) D_2 treatment is suspended and replaced by placebo therapy), mean serum PTH values markedly increase, reaching pretreatment levels. This study demonstrates that: (1) 1α -(OH) D_2 is effective in reducing serum PTH levels, and (2) 1α -(OH) D_2 is safer than currently used therapies, despite its higher dosages and concurrent use of high levels of oral calcium phosphate binder.

Example 6: Open Label Study of Elderly Subjects with Elevated Blood PTH from Secondary Hyperparathyroidism

[00114] Thirty elderly subjects with secondary hyperparathyroidism are enrolled in an open label study. The selected subjects have ages between 60 and 100 years and have elevated serum PTH levels (greater than the upper limit of young normal range). Subjects also have femoral neck osteopenia (femoral neck bone mineral density of ≤ 0.70 g/cm²).

[00115] Subjects are requested to keep a diet providing approximately 500 mg calcium per day without the use of calcium supplements. For a twelve week treatment period, subjects self-administer orally 2.5 μ g/day 1α -(OH) D_2 . At regular intervals throughout the treatment period, subjects are monitored for serum PTH levels, serum calcium and phosphorus, and urine calcium and phosphorus levels. Efficacy is evaluated by pre- and post-treatment comparisons of serum PTH levels. Safety is evaluated by serum and urine calcium and phosphorus values.

[00116] The administration of 1α -(OH) D_2 is shown to significantly reduce PTH levels with an insignificant incidence of hypercalcemia, hyperphosphatemia, hypercalciuria and hyperphosphaturia.

Example 7: Double Blind Study of Open Label Study of Elderly Subjects with Elevated Blood PTH from Secondary Hyperparathyroidism

[00117] A twelve month double-blind placebo-controlled clinical trial is conducted with forty subjects with secondary hyperparathyroidism. The selected subjects have ages between 60 and 100 years and have a history of secondary

-36-

hyperparathyroidism. Subjects also have femoral neck osteopenia (femoral neck bone mineral density of $\leq 0.70 \text{ g/cm}^2$).

[00118] All subjects enter a six-week control period after which the subjects are randomized into two treatment groups: one group receives a constant dosage of $15 \mu\text{g/day } 1\alpha,24\text{-(OH)}_2\text{D}_4$ (u.i.d.; a dosage greater than $7.5 \mu\text{g/day}$), and the other group receives a matching placebo. Both groups maintain a normal intake of dietary calcium without the use of calcium supplements. Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a) intact PTH (iPTH); (b) radial, femoral and spinal bone mineral density; and (c) bone-specific urine markers (e.g., pyridinium crosslinks). Safety is evaluated by (a) serum calcium and phosphorus, and (b) urine calcium and phosphorus.

[00119] Analysis of the clinical data show that $1\alpha,24\text{-(OH)}_2\text{D}_4$ significantly decreases iPTH and bone specific urine markers. Subjects treated with this compound show normal serum calcium levels and stable radial and spinal bone densities relative to baseline values. In contrast, patients treated with placebo show no reduction in iPTH and bone-specific urine markers. An insignificant incidence of hypercalcemia is observed in the treatment group.

Secondary and Tertiary Hyperparathyroidism Study

Example 8: Open Label Study of Renal Patients with Sufficiently Elevated Blood PTH from Secondary and Tertiary Hyperparathyroidism

[00120] Fourteen renal patients enrolled in a clinical trial to study secondary hyperparathyroidism showed baseline iPTH levels greater than 1000 pg/mL (range: $1015\text{-}4706 \text{ pg/mL}$). These greatly elevated levels indicated a component of the disease as tertiary (i.e., glandular enlargement but continued presence of vitamin D receptors) to the gland as well as a component secondary to the loss of renal function. The initial dose of $1\alpha\text{-(OH)}\text{D}_2$ ($10 \mu\text{g} - 3 \text{ times/week}$) was increased (maximum, $20 \mu\text{g} - 3 \text{ times/ week}$) or decreased as necessary to attain and maintain iPTH in the range of $150\text{-}300 \text{ pg/mL}$. After 11-12 weeks of treatment, the iPTH levels of all but two of the patients had decreased to below 1000 pg/mL , and the iPTH levels in nine of the patients had

-37-

decreased to below 510 pg/mL. There were no episodes of hypercalcemia with the patients during the study.

Example 9: Placebo-Controlled Study of Elderly Subjects with Elevated Blood PTH From 1,25(OH)₂D₃ Deficiency Associated With ARVDD Syndrome

[00121] Sixty elderly subjects with elevated PTH from 1,25(OH)₂D₃ deficiency associated with ARVDD syndrome are enrolled in a blind placebo-controlled study. The selected subjects have ages between 50 and 80 years and have elevated serum PTH levels (greater than the upper limit of normal range) and depressed serum 1,25(OH)₂D₃ levels (below the lower limit of normal range). Subjects also have femoral neck osteopenia (femoral neck bone mineral density of ≤ 0.70 g/cm²).

[00122] Subjects are requested to keep a diet providing approximately 500 mg of calcium per day and are not to use calcium supplements. For a twelve month treatment period, thirty subjects self-administer orally 20 μ g of 1 α -(OH)D₂ once per week; the other thirty subjects self-administer placebo capsules once per week. At regular intervals throughout the treatment period, subjects are monitored for femoral bone mineral density; serum PTH levels, calcium, phosphorus and osteocalcin; and urine calcium, phosphorus and hydroxyproline levels. Other safety parameters monitored include blood urea nitrogen, serum creatinine and creatinine clearance. Efficacy is evaluated by pre- and post-treatment comparisons of serum PTH levels and femoral neck bone mineral density. Safety is evaluated by serum and urine calcium and phosphorus values.

[00123] The administration of 1 α -(OH)D₂ is shown to significantly reduce PTH levels and stabilize or increase femoral neck bone mineral density with an insignificant incidence of hypercalcemia and hyperphosphatemia, and no effect on kidney function parameters.

Example 10: Placebo-Controlled Study of Elderly Subjects with Elevated Blood PTH From 1,25(OH)₂D₃ Deficiency Associated With ARVDD Syndrome

[00124] Sixty elderly subjects with elevated PTH from 1,25(OH)₂D₃ deficiency associated with ARVDD syndrome are enrolled in a blind placebo-controlled study. The

-38-

selected subjects have ages between 50 and 80 years and have elevated serum PTH levels (greater than the upper limit of normal range) and depressed serum $1,25(\text{OH})_2\text{D}_3$ levels (below the lower limit of normal range). Subjects also have femoral neck osteopenia (femoral neck bone mineral density of $\leq 0.70 \text{ g/cm}^2$).

[00125] Subjects are requested to keep a diet providing approximately 500 mg of calcium per day and are not to use calcium supplements. For a twelve month treatment period, thirty subjects self-administer orally $100 \mu\text{g}$ of $1,24(\text{OH})_2\text{D}_2$ once per week; the other thirty subjects self-administer placebo capsules once per week. At regular intervals throughout the treatment period, subjects are monitored for femoral bone mineral density; serum PTH levels, calcium, phosphorus and osteocalcin; and urine calcium, phosphorus and hydroxyproline levels. Other safety parameters monitored include blood urea nitrogen, serum creatinine and creatinine clearance. Efficacy is evaluated by pre- and post-treatment comparisons of serum PTH levels and femoral neck bone mineral density. Safety is evaluated by serum and urine calcium and phosphorus values.

[00126] The administration of $1,24(\text{OH})_2\text{D}_2$ is shown to significantly reduce PTH levels and stabilize or increase femoral neck bone mineral density with an insignificant incidence of hypercalcemia and hyperphosphatemia and no effect on kidney function parameters.

[00127] In summary, the present invention provides therapeutic methods for treating hyperparathyroidism associated with aging and/or ARVDD. The present invention also provides a method of treating and preventing one or more of the conditions included within the syndrome of ARVDD, e.g., (1) primary vitamin D deficiency, (2) $1,25-(\text{OH})_2\text{D}_3$ deficiency, and (3) $1,25-(\text{OH})_2\text{D}_3$ resistance. The methods are suitable for lowering elevated blood parathyroid hormone levels, or maintaining lowered blood PTH levels in subjects with ARVDD syndrome. The methods include administering an effective amount of an active vitamin D compound utilizing a variety of treatment protocols. The method in accordance with the present invention has significantly less resultant hypercalcemia and hyperphosphatemia.


-39-

[00128] While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.

-40-

CLAIMS

1. A method of treating hyperparathyroidism associated with aging, comprising administering to a subject suffering therefrom an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels.
2. A method in accordance with claim 1, wherein the hyperparathyroidism is associated with Aging-Related Vitamin D Deficiency (ARVDD) syndrome.
3. A method in accordance with claim 2, wherein the ARVDD syndrome includes one or more conditions which is (1) primary vitamin D deficiency, (2) 1,25-dihydroxyvitamin D₃ deficiency, and (3) 1,25-dihydroxyvitamin D₃ resistance.
4. A method in accordance with claim 2, wherein the active vitamin D is a hydroxyvitamin D compound of formula (I):



wherein A¹ and A² each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R¹ and R² are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R¹ and R² cannot both be an alkenyl, or taken together with the

carbon to which they are bonded, form a C₃-C₈ cyclocarbon ring; R³ is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X¹ is hydrogen or hydroxyl; X² is hydrogen or hydroxyl, or, is taken with R¹ or R², to constitute a double bond; X³ is hydrogen or hydroxyl provided that at least one of X¹, X² and X³ is hydroxyl.


5. A method in accordance with claim 3, wherein the compound of formula (I) is a hypocalcemic hydroxyvitamin D compound.
6. A method in accordance with claim 2, wherein the active vitamin D is a 1α -hydroxyvitamin D compound of formula (II):



wherein A¹ and A² each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R¹ and R² are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R¹ and R² cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C₃-C₈ cyclocarbon ring; R³ is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X¹ is hydrogen or hydroxyl, and X² is hydrogen or hydroxyl, or, is taken with R¹ or R², to constitute a double bond.

-42-

7. A method in accordance with claim 2, wherein the active vitamin D is a 24-hydroxyvitamin D compound of formula (IV):



wherein A^1 and A^2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R^1 and R^2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R^1 and R^2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C_3 - C_8 cyclocarbon ring; R^3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X^3 is hydrogen or hydroxyl; X^2 is hydrogen or hydroxyl; or, is taken with R^1 or R^2 , to constitute a double bond.

8. A method in accordance with claim 2 wherein the active vitamin D is 1 α -hydroxyvitamin D₄; 1 α ,25-dihydroxyvitamin D₂; 1 α -hydroxyvitamin D₂, 1 α ,24-dihydroxyvitamin D₂; 1 α ,24,25-trihydroxyvitamin D₂; 1 α ,25-dihydroxyvitamin D₃, 1 α -dihydroxyvitamin D₃; 1 α ,25-dihydroxyvitamin D₄; 1 α ,24,25-trihydroxyvitamin D₄; 24-hydroxyvitamin D₂; or 24-hydroxyvitamin D₄.

-43-


9. A method in accordance with claim 3 wherein the condition included with ARVDD syndrome is primary vitamin D deficiency.
10. A method in accordance with claim 3 wherein the condition included within ARVDD syndrome is 1,25-dihydroxyvitamin D₃ deficiency.
11. A method in accordance with claim 3 wherein the condition included within ARVDD syndrome is 1,25-dihydroxyvitamin D₃ resistance.
12. A method in accordance with claim 2 wherein the active vitamin D compound is co-administered with at least one agent characterized by said agent's ability to reduce loss of bone mass, or bone mineral content in patients.
13. A method in accordance with claim 12 wherein the agent is other vitamin D compounds, conjugated estrogens, sodium fluorides, bisphosphonates, cobalamin, pertussin toxin or boron.
14. A method in accordance with claim 12 wherein the vitamin D compound is administered before, after or concurrently with the other agent.
15. A method in accordance with claim 2 wherein the active vitamin D is administered in high dose on an intermittent or episodic dosing regime.
16. A method in accordance with claim 15 wherein the amount of active vitamin D is a high dose which is between about 10μg to about 300μg.
17. A method in accordance with claim 16 wherein the active vitamin D compound is 1α,25-dihydroxyvitamin D₃ or 1α-dihydroxyvitamin D₃.
18. A method in accordance with claim 15 wherein the high dose is administered once per week to once every 12 weeks.
19. A method in accordance with claim 2 wherein the amount of the vitamin D compound is administered parenterally or orally in combination with a pharmaceutically acceptable carrier.

-44-

20. A method in accordance with claim 19 wherein the amount of vitamin D compound is administered parenterally.
21. A method in accordance with claim 20 wherein the amount of vitamin D compound is administered intravenously.
22. A method in accordance with claim 19 wherein the active vitamin D compound is administered orally.
23. A method in accordance with claim 20 wherein the active vitamin D compound is administered in an episodic dose of about 1 μ g to about 300 μ g.
24. A method in accordance with claim 23 wherein the active vitamin D compound is administered in an episodic dose of about 20 μ g to about 100 μ g.
25. A method in accordance with claim 19 wherein the active vitamin D compound is co-administered with a phosphate binder.
26. The method of claim 20 wherein the active vitamin D compound is administered is by intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption.
27. A method of treating one or more conditions included within aging-related vitamin D deficiency (ARVDD) syndrome in a subject suffering therefrom comprising, administering to the subject an amount of active vitamin D compound sufficient to lower elevated or maintain lowered serum parathyroid hormone levels.
28. A method in accordance with claim 27 wherein the active vitamin D compound is co-administered with at least one agent characterized by the agent's ability to reduce loss of bone mass or bone mineral content in patients experiencing or tending toward the loss of bone mass or bone mineral content.

-45-

29. A serum parathyroid hormone level lowering composition, in unit dosage form, comprising an effective amount of a compound of formula (III):



wherein A¹ and A² are either hydrogen or together represent a carbon-carbon double bond between C-22 and C-23; and X¹ is hydrogen or hydroxyl, said effective amount comprising about 1 µg to about 300 µg in unit dosage form, and a pharmaceutically acceptable vehicle for the compound, wherein the amount is effective to lower elevated or maintain lowered serum parathyroid hormone levels of a human in need thereof, following administration thereto.

30. The composition claimed in claim 29 which further comprises, at least one co-administerable agent characterized by the agent's ability to reduce loss of bone mass or bone mineral content in mammals experiencing or tending toward the loss of bone mass or bone mineral content.

31. The composition as claimed in claim 30, wherein the agent is conjugated estrogens, calcitonin, sodium fluorides, bisphosphonates, calcium supplements, cobalamin, pertussin toxin or boron.

32. A co-administerable pharmaceutical combination which comprises the composition of claim 29, and a phosphate binder.

-46-

33. The combination of claim 32 wherein said phosphate binder is calcium carbonate or calcium acetate.

34. A method of ameliorating or preventing hyperparathyroidism associated with ARVDD in a subject suffering therefrom, comprising administering to the subject an amount of an active vitamin D compound sufficient to suppress elevated parathyroid activity.

35. A co-administrable pharmaceutical combination comprising (i) a hypocalcemic vitamin D compound and (ii) a bone agent which is conjugated estrogens, calcitonin, sodium fluorides, bisphosphonates, calcium supplements, cobalamin, pertussin toxin or boron.

36. A combination in accordance with claim 35 wherein the vitamin D compound is administered before, after or concurrently with the bone agent.

37. Method of treating 1,25-(OH)₂ D₃ resistance in a subject suffering therefrom comprising, administering to the subject an effective amount of an active vitamin D compound wherein the active vitamin D is administered in high dose on an intermittent dosing regime.

38. A combined pharmaceutical preparation comprising an active vitamin D compound and a bone agent, the preparation being adapted for the administration of the active vitamin D on an episodic basis, and the administration of the bone agent on a daily or episodic basis, to a subject having hyperparathyroidism and/or ARVDD.

39. A pharmaceutical packaging, comprising (i) a plurality of containers therein, at least one of the containers containing an active vitamin D compound, and at least one of the containers containing a bone agent, and (ii) instructions for co-administering the active vitamin D compound and the bone agent to a subject having hyperparathyroidism and/or ARVDD.